DISCO Pharmaceuticals
DISCO Pharmaceutical's pioneering surfaceome mapping platform identifies proteins and protein communities across the entire cancer cell surface in a scalable way, boosting the discovery of meaningful targets for both mono- and bi-specific antibodies. These insights enable the development of countless cancer-selective therapies, with the potential to increase efficacy and reduce side effects for patients. DISCO is creating an internal pipeline of novel anti-cancer therapeutics leveraging this knowledge.
Sector
Biopharmaceuticals
Strategies
Capital
Status
Live
Website
discopharma.de
SofinnovaCapital
The Sofinnova Capital Strategy is our flagship fund, investing as founding or lead investor in early-stage biopharma and medtech start-ups developing groundbreaking therapeutic technologies.
SofinnovaMD Start
The Sofinnova MD Start Strategy is our in-house medtech accelerator focused on creating and launching early-stage medtech companies through hands-on company building.
SofinnovaCrossover
The Sofinnova Crossover Strategy invests in growth-stage biotech and medtech companies that have clinically validated their technologies and are preparing for commercialization.
SofinnovaIndustrial Biotech
Our Industrial Biotech Strategy invests in early-stage sustainable companies across the agriculture, chemicals, food and materials sectors.
SofinnovaTelethon
The Sofinnova Telethon Strategy makes early-stage investments in leading Italian science for the benefit of patients around the world.
SofinnovaDigital Medicine
Our Digital Medicine Strategy backs early-stage techbio and healthtech start-ups at the intersection of biology, data, and computation.
SofinnovaBiovelocita
The Sofinnova Biovelocita Strategy is our biotech accelerator, partnering with leading research organizations to create and build European biotech start-ups.